EPI-321
Biologic
EPI-321 is one of 7 biologic programs targeting Facioscapulohumeral Muscular Dystrophy. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Facioscapulohumeral Muscular Dystrophy
#DrugCompanyPhaseTrials
1Losmapimod
GSKPhase 2
RO7204239
RochePhase 2
ACE-083
Merck & Co.Phase 2
AOC 1020
AAvidity Biosciences, Inc.
Phase 2
ATYR1940
AaTyr Pharma, Inc.
Phase 2
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
EPI-321
EEpicrispr Biotechnologies, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EPI-321. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company
- EEpicrispr Biotechnologies, Inc.